Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Translational Aspects of Epithelioid Sarcoma: Current Consensus.
Grünewald TGP, Postel-Vinay S, Nakayama RT, Berlow NE, Bolzicco A, Cerullo V, Dermawan JK, Frezza AM, Italiano A, Jin JX, Le Loarer F, Martin-Broto J, Pecora A, Perez-Martinez A, Tam YB, Tirode F, Trama A, Pasquali S, Vescia M, Wortmann L, Wortmann M, Yoshida A, Webb K, Huang PH, Keller C, Antonescu CR. Grünewald TGP, et al. Among authors: postel vinay s. Clin Cancer Res. 2024 Mar 15;30(6):1079-1092. doi: 10.1158/1078-0432.CCR-23-2174. Clin Cancer Res. 2024. PMID: 37916971 Review.
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS. Molife LR, et al. Br J Cancer. 2010 Jul 27;103(3):332-9. doi: 10.1038/sj.bjc.6605767. Epub 2010 Jul 13. Br J Cancer. 2010. PMID: 20628389 Free PMC article. Clinical Trial.
Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door.
Verlingue L, Hollebecque A, Lacroix L, Postel-Vinay S, Varga A, El Dakdouki Y, Baldini C, Balheda R, Gazzah A, Michot JM, Marabelle A, Mir O, Arnedos M, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, André F, Deutsch E, Scoazec JY, Soria JC, Massard C. Verlingue L, et al. Eur J Cancer. 2018 Mar;92:1-10. doi: 10.1016/j.ejca.2017.12.020. Epub 2018 Feb 3. Eur J Cancer. 2018. PMID: 29413684
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).
Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferté C. Sun R, et al. Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18. Eur J Cancer. 2017. PMID: 28826073
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, Massard C, Fuerea A, Ribrag V, Gazzah A, Armand JP, Amellal N, Angevin E, Noel N, Boutros C, Mateus C, Robert C, Soria JC, Marabelle A, Lambotte O. Michot JM, et al. Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5. Eur J Cancer. 2016. PMID: 26765102 Review.
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.
Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P. Olmos D, et al. Lancet Oncol. 2010 Feb;11(2):129-35. doi: 10.1016/S1470-2045(09)70354-7. Epub 2009 Dec 23. Lancet Oncol. 2010. PMID: 20036194 Free PMC article. Clinical Trial.
Profile and outcome of cancer patients enrolled in contemporary phase I trials.
Alouani E, Gazzah A, Mercier S, Bahleda R, Hollebecque A, Michot JM, Baldini C, Ammari S, Champiat S, Marabelle A, Postel-Vinay S, Ribrag V, Loriot Y, Aix SP, Mahjoubi L. Alouani E, et al. Among authors: postel vinay s. Eur J Cancer. 2023 Jul;188:1-7. doi: 10.1016/j.ejca.2023.04.006. Epub 2023 Apr 20. Eur J Cancer. 2023. PMID: 37178645 Clinical Trial.
AXL and acquired resistance to EGFR inhibitors.
Postel-Vinay S, Ashworth A. Postel-Vinay S, et al. Nat Genet. 2012 Jul 27;44(8):835-6. doi: 10.1038/ng.2362. Nat Genet. 2012. PMID: 22836088 No abstract available.
Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ. Holme H, et al. Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8. Sci Rep. 2018. PMID: 30131505 Free PMC article.
112 results